Alector Inc. (ALEC) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Alector Inc. (ALEC)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

1.63

-0.16 (-8.94%)

At close: Jan 14, 2025, 3:59 PM

1.70

4.29%

After-hours Jan 14, 2025, 07:51 PM EST

undefined% (undefined)

Bid	1.6
Market Cap	159.63M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.71
PE Ratio (ttm)	-0.95
Forward PE	n/a
Analyst	Buy

Ask	1.63
Volume	701,674
Avg. Volume (20D)	1,314,491
Open	1.82
Previous Close	1.79
Day's Range	1.61 - 1.82
52-Week Range	1.61 - 7.78
Beta	undefined

About ALEC

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, a humanized recombinant monoclonal antibody, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, incl...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Feb 7, 2019

Employees 241

Stock Exchange NASDAQ

Ticker Symbol ALEC

Website https://www.alector.com

Analyst Forecast

According to 5 analyst ratings, the average rating for ALEC stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 145.40% from the latest price.

Buy 60.00%

Hold 20.00%

Sell 20.00%

Stock Forecasts

Next Earnings Release

Alector Inc. is scheduled to release its earnings on Feb 25, 2025, during market hours.
Analysts project revenue of $16.80M, reflecting a 10.60% YoY growth and earnings per share of -0.61, making a 24.49% increase YoY.

Why Price Moved

1 month ago · Source

-13.1%

Alector shares are trading lower after the company... Unlock content with Pro Subscription

1 month ago · Source

-35.1%

Alector shares are trading lower after the company announced that the INVOKE-2 Phase 2 clinical trial evaluating the safety and efficacy of AL002 in individuals with early Alzheimer's disease failed to meet its primary endpoint.

News

1 month ago · benzinga.com

Neurology-Focused Alector Downgraded On Failed Alzheimer's Study, BofA Securities Highlights Lack Of Catalysts

Bank of America Securities has downgraded Alector, Inc. ALEC, citing the failure of its AL002 program.

1 month ago · zacks.com

ALEC Stock Tanks as Alzheimer's Drug Fails in Mid-Stage Study

Alector stock falls as the phase II INVOKE-2 study evaluating AL002 in slowing disease progression in early Alzheimer's disease fails to meet the primary goal.

1 month ago · benzinga.com

Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce

On Monday, Alector, Inc. ALEC released results from the INVOKE-2 Phase 2 trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer's disease...

2 months ago · zacks.com

Alector (ALEC) Reports Q3 Loss, Misses Revenue Estimates

Alector (ALEC) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.53 per share a year ago.

2 months ago · businesswire.com

Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach

OKLAHOMA CITY--(BUSINESS WIRE)-- #FedermanSherwood--Federman & Sherwood Investigates Abbott Laboratories Employees Credit Union (“ALEC”) for Data Breach.